The latest news

On the morning of April 26th, Cheng Lianyuan, member of the Standing Committee of Yunnan Provincial Party Committee and secretary of Kunming Municipal Party Committee, Xia Junsong, member of the Standing Committee of Kunming Municipal Party Committee and secretary general of Kunming Municipal Party Committee, Zhang Bin, member of the Standing Committee of Yunnan Municipal Party Committee and executive deputy mayor, and other eight people visited HMI Investment Group (hereinafter referred to as "HMI Group") to inspect and guide its work.

Tan Xin, Chairman of HMI Group, on behalf of the enterprise, extended a warm welcome to Cheng Lianyuan and other leaders who came to our company for investigation and guidance, and reported in detail the upstream and downstream layout, domestic and foreign policies and regulations and market prospects of Hemp Group in the industrial hemp industry. Wang Shubin, general manager of Beijing Hanyi Bio-technology Ltd. Co., a wholly-owned subsidiary of HMI Group, Xie Xintong, director of investment division of HMI Group, and Du Yesong, secretary of the board of directors of Dezhan Healthcare Co., Ltd., a strategic partner of HMI Group, attended the meeting.

Secretary Cheng Lianyuan fully affirmed the investment direction of industrial hemp industry based on biopharmaceuticals of HMI Group, and agreed with the layout of four application supports of HMI Group in new tobacco, food health care, daily chemicals and fiber products. Cheng Shuji said that as a government, it should actively guide the sound development of industry, and provide all-round support for enterprises from the aspects of formulating laws and regulations, checking core germplasm resources and supporting services. The atmosphere of the meeting was warm, and the leaders of relevant departments expressed their opinions, listened to the voices of enterprises, offered suggestions on the spot, and solved problems.

General situation of HMI group

Hanma Investment Group Co., Ltd. (HMI Group) is committed to "promoting the industrial revolution of biomass instead of minerals and becoming the world leader in comprehensive application of hemp industry!" . As a leading international and domestic industry leader, HMI Group opposes the legalization of all forms of recreational hemp. Over the years, HMI Group has made positive contributions to legally promoting the vigorous development of industrial and medical use of hemp industry in China, and has made great achievements in setting industry standards and norms. At present, HMI Group is a legal investment group in China, which is based on the whole industrial chain layout of industrial hemp and oriented towards biopharmaceuticals.

As a unicorn in this industry, HMI Group focuses on the whole industrial chain investment of industrial hemp, and carries out breeding, planting, extraction, R&D, production and sales worldwide. The industry covers biopharmaceuticals, food, health products, beauty cosmetics, medical devices, textiles, new materials and many other fields. At the same time, HMI Group has continuously deepened its industry analysis and industrial layout, actively carried out technology and product iteration, devoted itself to researching and implementing the "patent pool" strategy, strengthened the creation and application of intellectual property rights, expanded its social influence by setting up a media information platform, effectively built a global product sales network, and steadily entered the global market.

HMI Group has built an interdependent and mutually beneficial upstream and downstream industrial value chain for the comprehensive utilization of hemp plants.

In the field of breeding and planting, Yunnan Suma Biotechnology Co., Ltd. and Heilongjiang Hanzheng Hemp Technology Co., Ltd. were invested and established, and the Industrial Hemp Planting License issued by the Public Security Department was obtained. HMI Group, together with hemp research institute of Chinese Academy of Agricultural Sciences, Heilongjiang Academy of Sciences and other scientific research units, set up demonstration bases for medical hemp and fiber hemp breeding in Yunnan and Heilongjiang provinces, actively advocated the construction of "National Hemp Germplasm Gene Bank", collected the germplasm resources of hemp plants and their related wild plants, and laid a foundation for cultivating hemp varieties that meet China's industrial management policies and industrial standards and promoting their application. At present, the fiber hemp variety "Hemp No.1" has obtained the Crop Variety Registration Certificate in Heilongjiang Province, and the cultivated area has exceeded 100,000 mu. The medical hemp variety "Hemp No.1" with high content of cannabidiol has entered the breeding stage.

In terms of raw material extraction of medical hemp, Yunnan Hansu Biotechnology Co., Ltd. (referred to as HSBT ), a subsidiary of HMI Group, invested in Kunming to build the world's large-scale industrial hemp bio-extraction and separation base meeting GMP standards. It passed the acceptance of various administrative departments and the Anti-drug Bureau of the Provincial Public Security Department and obtained the Industrial Hemp Mosaic Processing License. By using alcohol-soluble fluid crystallization technology, Hanbitol, a non-psychoactive component of cannabidiol (CBD), which has positive significance and far-reaching influence on medical and health industries, was extracted and separated from industrial hemp leaves. At present, this base is the world's single cannabidiol and other cannabinoids extraction factory, which can extract and separate a variety of effective components without psychoactive activities, and it is also the world's factory that can industrially extract geranyl flavone A from hemp. The extraction of pharmaceutical raw materials from hemp, a technological route that had never been tried before, was finally succeeded by HSBT, which became an industry benchmark and a demonstration project of Yunnan Anti-drug Bureau.

The extraction plant of HMI Group invested and built in Nevada, USA, has obtained the breeding, planting and extraction license issued by the U.S. government, and is located in Las Vegas. The layout of China and the United States has made the biopharmaceutical preparation technology of Hansu Biotech internationalized. Next, HMI Group will participate in the medical hemp industry investment in Canada at the invitation of the Canadian government, and the global industrialization layout in Britain, Australia and Japan has already begun.

HSBT pays attention to expanding the domestic and international markets, and the completion of the extraction and separation base has provided reliable raw materials and technological guarantee for exploring and overcoming intractable diseases such as cancer, Parkinson's disease, Alzheimer's disease, depression and epilepsy, and laid a foundation for future biopharmaceuticals. At present, Meirui Health (stock code: HK02327), a Hong Kong-listed company, has invested 25.55% of HSBT.

HMI Group, which has the full license of industrial hemp and the resources of core varieties, has set up Hanyi Biotechnology (Beijing) Co., Ltd. (HYBT) in order to serve the national big health strategy. HYBT is a biopharmaceutical enterprise mainly engaged in cannabinoid-based drug research, drug development and commercial operation. It has been recognized as Beijing High-tech Enterprise, Zhongguancun High-tech Enterprise, Beijing Science and Technology Small and Medium-sized Enterprise, Zhongguancun Gazelle Enterprise from 2020 to 2021, and Beijing Patent Pilot Unit by the national authorities.

As an R&D-driven enterprise, HYBT has established a leading platform for all-round research and development of cannabinoids. In 2017, it also established "Academician Expert Workstation" in cooperation with Academician Yang Baofeng, an academician of Chinese Academy of Engineering and a famous pharmacology expert. It is dedicated to the research on the correlation between the material basis and activity of industrial hemp, and further explores and explores the application of high value-added components in industrial hemp plants in the field of biopharmaceuticals. At present, medicinal research on cannabinoids has been carried out in key areas such as anti-epilepsy, anti-pulmonary hypertension, anti-depression, anti-Alzheimer's disease, anti-pancreatic cancer, anti-Parkinson's disease and rare diseases, and staged progress has been made. Among them, the "Ten Diseases and Ten Drugs" project funded by Beijing Municipal Science and Technology Commission-the new anti-epileptic drug hemp Polyphenol Soft Capsule project has completed the preclinical research. In addition, fruitful results have been achieved in the field of cannabinoid application technology. The self-developed extraction technology of nontoxic active ingredients of industrial hemp has obtained international patents and has been successfully applied to industrial production. The successful water-soluble technology of cannabidiol has significantly improved the bioavailability of cannabidiol. The successful atomization technology of cannabinoids and the ongoing transdermal drug delivery technology will greatly broaden the application scenarios of industrial hemp.

With cannabinoid drug development as the core, HYBT has actively carried out original research work, and applied for more than 100 patents at home and abroad in cannabinoid new drug research and applied technology development, and have grown into a biopharmaceutical company in a fast-developing track. HYBT has set up a platform for R&D and sales of food and health products, and signed an agreement with Canadian hemp Full License Company to set up a joint venture pet products company to develop and sell a series of products such as pet health products, snacks, hair care, etc., and strive to quickly transform non-pharmaceutical technical achievements into fast-moving consumer goods such as food and health products and pet products, thus providing a strong cash flow support for enterprises' continuous investment in pharmaceutical R&D, technology iteration and other scientific research. HMI Group has reached joint ventures or cooperation with many industry leaders and listed companies, and the downstream industries have entered the stage of value export.

Hemp Group insists on "scientific and technological innovation" as the core driving force, and accelerates the radiation development base in an all-round way, so as to realize the group's "globalization strategy". Adhering to the spirit of deep cultivation in the industry, Hemp Group will continue to explore in the fields of biopharmaceuticals and life sciences, and inject new vitality into the economic development engine of the national health industry.

Our mission: to promote the industrial revolution of biomass instead of minerals.

Our vision: to be a world leader in comprehensive application of hemp industry.

Our core values: an industry, a lifelong career!